In Ningbo's latest government work report, biopharmaceuticals have emerged as a key focus. As part of the 2026 agenda, the city aims to accelerate the growth of emerging industries, including biopharmaceuticals.

Enzymaster (Ningbo) Bio-Engineering, a high-tech enterprise specializing in biomanufacturing, has been rooted in Ningbo for 13 years. The company focuses on enzymes, known as the "chips of biomanufacturing", using synthetic biology technology to produce various compounds.

Enzymes, protein-based biological catalysts, are essential in industries like pharmaceuticals and food additives. Founded in 2013, Enzymaster innovates by designing "specialized enzymes" with higher catalytic efficiency and stability for mass production compared with natural enzymes, addressing market demands.

In 2021, Enzymaster launched the EnzyAI platform, leveraging AI to analyze vast enzyme gene data and discover optimal enzyme evolution formulas. This AI-driven approach has significantly enhanced its R&D efficiency.

Last year, a joint lab with the Shenzhen University of Advanced Technology was established to create a predictive, programmable smart biomanufacturing platform. Enzymaster also collaborated with a team from the Eastern Institute of Technology, Ningbo to explore marine biomanufacturing.

Enzymaster has already commercialized over 20 products, including pharmaceutical intermediates and food additives.

It now serves major pharmaceutical firms, including AstraZeneca, Bayer, and Merck, expanding its reach globally.

With plans for a 2026 IPO and ongoing expansion, the company is poised to transform biomanufacturing, supporting global health and sustainability goals with its innovative enzyme solutions.